MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer speaks to Proactive's Andrew Scott soon after announcing positive results from a pre-clinical study of ArtemiCTM on rats with no pathological changes or differences between the study groups reported. He also discusses its first-ever shipments of the Mercury Pharma line, which includes high THC products, directly to patients in Brazil through a binding supply and distribution agreement with ONIX Empreendimentos e Participações.
viewMGC Pharmaceuticals Ltd
MGC Pharma updates on ArtemiC coronavirus study and first-ever THC shipment to Brazil
Quick facts: MGC Pharmaceuticals Ltd
Price: 0.022 AUD
ASX:MXC
Market: ASX
Market Cap: $36.38 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
MGC Pharmaceuticals leads the way in phytocannabinoid derived medicines
Most read
Mining
Proactive to host Gold Webinar on Tuesday November 24 as strong market...
6 days, 21 hours ago
Health
MGC Pharmaceuticals acquires Australian telehealth platform Medicinal...
3 days, 21 hours ago
Mining
Musgrave Minerals turns up the heat at Cue Gold Project with new discovery...
4 days, 1 hour ago
Tech
Sparc Technologies makes strong ASX debut with shares up to 90% above IPO price
3 days, 21 hours ago
